Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance

Cells. 2022 Oct 20;11(20):3305. doi: 10.3390/cells11203305.

Abstract

Ovarian Cancer (OVCA) is the most fatal gynecologic cancer and has a 5-year survival rate less than 45%. This is mainly due to late diagnosis and drug resistance. Overexpression of plasma gelsolin (pGSN) is key contributing factor to OVCA chemoresistance and immunosuppression. Gelsolin (GSN) is a multifunctional protein that regulates the activity of actin filaments by cleavage, capping, and nucleation. Generally, it plays an important role in cytoskeletal remodeling. GSN has three isoforms: cytosolic GSN, plasma GSN (pGSN), and gelsolin-3. Exosomes containing pGSN are released and contribute to the progression of OVCA. This review describes how pGSN overexpression inhibits chemotherapy-induced apoptosis and triggers positive feedback loops of pGSN expression. It also describes the mechanisms by which exosomal pGSN promotes apoptosis and dysfunction in tumor-killing immune cells. A discussion on the potential of pGSN as a prognostic, diagnostic, and therapeutic marker is also presented herein.

Keywords: T cells; apoptosis; chemoresistance; extracellular vesicles (EVs); immune cells; macrophages; ovarian cancer; plasma gelsolin (pGSN); tumor microenvironment (TME).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Drug Resistance, Neoplasm
  • Female
  • Gelsolin / metabolism
  • Humans
  • Ovarian Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Gelsolin
  • Antineoplastic Agents

Grants and funding